http://harrismartin.com/article/17995/eli-lilly-says-distributor-...

  1. 494 Posts.
    http://harrismartin.com/article/17995/eli-lilly-says-distributor-of-axiron-testosterone-product-cant-be-sued-over-cardiovascular-risks/

    Eli Lilly Says Distributor of Axiron Testosterone Product Can’t be Sued Over Cardiovascular Risks
    May 14, 2014

    SAN FRANCISCO — The manufacturer of prescription testosterone Axiron has removed a lawsuit filed against it to federal court in California, arguing that a drug distributor and co-defendant was fraudulently joined to the case because it assumed no duty to warn of alleged cardiovascular risks associated with the product.

    Eli Lilly and Co. argues in its May 12 notice that none of the allegations in the lawsuit point directly to distributor McKesson Corp.’s liability for the deep vein thrombosis that afflicted plaintiff John Nagel after he used Axiron gel for more than a year.

    As a result, the Indiana-based drug ...

    Sorry - don't have access to the full article - please post full article if you do!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.8¢
Change
0.000(0.00%)
Mkt cap ! $7.366M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
5 883823 1.7¢
 

Sellers (Offers)

Price($) Vol. No.
1.8¢ 500697 1
View Market Depth
Last trade - 16.21pm 30/07/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.